|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta S, Kong W, Peng Y, Miao Q and
Mackillop WJ: Temporal trends in the incidence and survival of
cancers of the upper aerodigestive tract in Ontario and the United
States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moreira J, Tobias A, O'Brien MP and
Agulnik M: Targeted therapy in head and neck cancer: An update on
current clinical developments in epidermal growth factor
receptor-targeted therapy and immunotherapies. Drugs. 77:843–857.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2017. View Article : Google Scholar
|
|
6
|
Fulda S: Promises and challenges of smac
mimetics as cancer therapeutics. Clin Cancer Res. 21:5030–5036.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Derakhshan A, Chen Z and Van Waes C:
Therapeutic small molecules target inhibitor of apoptosis proteins
in cancers with deregulation of extrinsic and intrinsic cell death
pathways. Clin Cancer Res. 23:1379–1387. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu J and Zhang L: Apoptosis in human
cancer cells. Curr Opin Oncol. 16:19–24. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun Q, Zheng X, Zhang L and Yu J: Smac
modulates chemosensitivity in head and neck cancer cells through
the mitochondrial apoptotic pathway. Clin Cancer Res. 17:2361–2372.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang XH, Feng ZE, Yan M, Hanada S, Zuo H,
Yang CZ, Han ZG, Guo W, Chen WT and Zhang P: XIAP is a predictor of
cisplatin-based chemotherapy response and prognosis for patients
with advanced head and neck cancer. PLoS One. 7:e316012012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matzinger O, Viertl D, Tsoutsou P, Kadi L,
Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G and
Bourhis J: The radiosensitizing activity of the SMAC-mimetic, Debio
1143, is TNFα-mediated in head and neck squamous cell carcinoma.
Radiother Oncol. 116:495–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eytan DF, Snow GE, Carlson SG, Schiltz S,
Chen Z and Van Waes C: Combination effects of SMAC mimetic
birinapant with TNFα, TRAIL, and docetaxel in preclinical models of
HNSCC. Laryngoscope. 125:E118–E124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Medicine USNLo: ClinicalTrials.gov, . U.S.
National Library of Medicine. Rockville Pike, Bethesda: 2017,
https://clinicaltrials.gov/ct2/results?cond=solid&term=smac&cntry1=&state1=&Search=SearchAugust
7–2017
|
|
15
|
Brands RC, Herbst F, Hartmann S, Seher A,
Linz C, Kübler AC and Müller-Richter UDA: Cytotoxic effects of
SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
Clin Oral Investig. 20:2325–2332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brands RC, Muller-Richter UD, De Donno F,
Seher A, Mutzbauer G, Linz C, Kübler AC and Hartmann S:
Co-treatment of wild-type EGFR head and neck cancer cell lines with
afatinib and cisplatin. Mol Med Rep. 13:2338–2344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eytan DF, Snow GE, Carlson S, Derakhshan
A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, et
al: SMAC mimetic birinapant plus radiation eradicates human head
and neck cancers with genomic amplifications of cell death genes
FADD and BIRC2. Cancer Res. 76:5442–5454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adelstein DJ, Li Y, Adams GL, Wagner H Jr,
Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup
phase III comparison of standard radiation therapy and two
schedules of concurrent chemoradiotherapy in patients with
unresectable squamous cell head and neck cancer. J Clin Oncol.
21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Samarasinghe B: Hallmarks of Cancer 3:
Evading Apoptosis. Scientific American. 2013.https://blogs.scientificamerican.com/guest-blog/hallmarks-of-cancer-3-evading-apoptosis/August
7–2017
|
|
20
|
De Maria S, Pannone G, Bufo P, Santoro A,
Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM,
Staibano S, et al: Survivin gene-expression and splicing isoforms
in oral squamous cell carcinoma. J Cancer Res Clin Oncol.
135:107–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khan Z and Bisen PS: Oncoapoptotic
signaling and deregulated target genes in cancers: Special
reference to oral cancer. Biochim Biophys Acta. 1836:123–145.
2013.PubMed/NCBI
|
|
22
|
Chen DJ and Huerta S: Smac mimetics as new
cancer therapeutics. Anticancer Drugs. 20:646–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koff JL, Ramachandiran S and
Bernal-Mizrachi L: A time to kill: Targeting apoptosis in cancer.
Int J Mol Sci. 16:2942–2955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amaravadi RK, Schilder RJ, Martin LP,
Levin M, Graham MA, Weng DE and Adjei AA: A phase I study of the
SMAC-mimetic birinapant in adults with refractory solid tumors or
lymphoma. Mol Cancer Ther. 14:2569–2675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Infante JR, Dees EC, Olszanski AJ, Dhuria
SV, Sen S, Cameron S and Cohen RB: Phase I dose-escalation study of
LCL161, an oral inhibitor of apoptosis proteins inhibitor, in
patients with advanced solid tumors. J Clin Oncol. 32:3103–3110.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tolcher AW, Bendell JC, Papadopoulos KP,
Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC,
Peale F, et al: A phase I dose-escalation study evaluating the
safety tolerability and pharmacokinetics of CUDC-427, a potent,
oral, monovalent IAP antagonist, in patients with refractory solid
tumors. Clin Cancer Res. 22:4567–4573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Khan Z, Khan N, Tiwari RP, Patro IK,
Prasad GB and Bisen PS: Down-regulation of survivin by oxaliplatin
diminishes radioresistance of head and neck squamous carcinoma
cells. Radiother Oncol. 96:267–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qi G, Kudo Y, Ando T, Tsunematsu T,
Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I and
Takata T: Nuclear Survivin expression is correlated with malignant
behaviors of head and neck cancer together with Aurora-B. Oral
Oncol. 46:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khan Z, Tiwari RP, Khan N, Prasad GB and
Bisen PS: Induction of apoptosis and sensitization of head and neck
squamous carcinoma cells to cisplatin by targeting survivin gene
expression. Curr Gene Ther. 12:444–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Irmler M, Thome M, Hahne M, Schneider P,
Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C,
et al: Inhibition of death receptor signals by cellular FLIP.
Nature. 388:190–195. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kataoka T, Budd RC, Holler N, Thome M,
Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M
and Tschopp J: The caspase-8 inhibitor FLIP promotes activation of
NF-kappaB and Erk signaling pathways. Curr Biol. 10:640–648. 2000.
View Article : Google Scholar : PubMed/NCBI
|
